Therefore, new-generation ALK inhibitors are already been developed and tested for NB therapy, for example, lorlatinib (NCT03107988)32, AZD3463 (ref. 33), and ceritinib (NCT01742286)34. This evidence concerns the gene ALK and neuroblastoma.